Used in research settings as a dual-acting compound combining DNA alkylating and histone deacetylase (HDAC) inhibiting properties. This combination makes it a candidate for studying anticancer therapies, particularly in preclinical models of hematological malignancies and solid tumors. It has shown activity in inducing apoptosis and cell cycle arrest in cancer cell lines. Its unique mechanism allows exploration in overcoming drug resistance in chemotherapy. Currently, it is not approved for clinical use and remains under investigation for potential oncology applications.